There is currently minimal therapeutic intervention available for<unk> . Patients are closely monitored for infections and for signs of monoclonal or oligoclonal B cell expansion that could indicate B cell malignancy. Splenectomy is unlikely to reduce B cell burden; peripheral blood B cell counts rose significantly in three patients who underwent the procedure. It remains to be determined whether immunosuppressive drugs, including B cell-depleting drugs such as rituximab, could be effective for treating<unk> .
BENTA disease
Degos disease
Pogosta disease
TRIANGLE disease
Bahima disease
Fox–Fordyce disease
Cruveilhier–Baumgarten disease
Borna disease